Hanergy

Henergy Biopharmaceutical, also known as Beijing Henokang, is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics. The company primarily targets viral infections, metabolic diseases, and central nervous system disorders, with a significant emphasis on high-unmet-need areas such as influenza and chronic hepatitis B. Its lead candidate, HNK-010, is a novel cap-dependent endonuclease inhibitor currently in clinical development for the treatment of influenza. Henergy leverages its internal R&D capabilities to advance a diverse pipeline that includes capsid assembly inhibitors for HBV and thyroid hormone receptor agonists for NASH. Headquartered in Beijing, the company aims to provide globally competitive treatments through rigorous scientific innovation.